Novo Nordisk facing pressure as study finds $1k drug can be made for $5
fortune.com
fortune.com
Researching it is... And you are not paid for your research "up front". It's added to the cost afterwards.
In general, mono-dimensional arguments merit an extra dose of skepticism from the audience.
Or does anybody actually believe FDA approval is very easy and cheap to come by these days?
That is to say that's it's not that expensive to R&D it, certainly compared to the eventual sale price, but it's carrying the cost of the hundred potential drugs that never made it to market that's the killer.
And the approval rate is less than 12%.
The crazy pricing is to compensate for the failed projects.
Also, it's not like you can bootstrap yourself or grow organically like Startups.
You have to wait for like 10 - 15 years. To actually start selling it.
[1]: https://www.google.com/amp/s/www.policymed.com/amp/2014/12/a...
So if they have a effectively built monopoly, chopping down the maximum they can charge via regulation would seem sensible wouldn’t it?
There's several factors that impact US drug prices. For instance FDA approvals are significantly more costly than EMA ones and the bargaining power of healthcare providers is worse compared to a single payer system
I have no knowledge of US laws, but I wouldn't be surprised if there's some kind of law preventing government interference with "the free market"
(It’s almost the opposite, in fact, where our courts have expanded the Commerce Clause over time to allow the federal government the ability to regulate close to any economic activity.)
Factor in the failed programs and you’re looking at about $2B of spend in order to bring a drug to market.
Several drug developments are halted before they reach market. Novo for instance lost a lot of money on their bet to develop inhalable insulin 15 years ago
That cost also has to be recouped when finally hitting the jackpot
So the whole "American big pharma needs to make a billion dollars a week in profit to recoup their R&D" is nothing but marketing fluff.
I would think any company - regardless of where it’s headquartered - would seek to recoup R&D costs in a huge market like the US where prices aren’t capped by the government.
I haven’t seen anyone say American pharma companies in particular need to make a ton of money.
The American-specific topic is that American consumers pay a ton more for drugs. That can be chalked up to lack of single-payer making American consumers incredibly easy to bully/negotiate against + all the rent-seekers who sit at various points along the care delivery system.
Not saying that it's not a screwed up industry, but stories like these distort the problem as well
If we split the profits across all of the people that "deserve reimbursement" you usually end up with a few dollars per person. Definitely, not enough to make a meaningful impact.
Additionally, the American consumer subsidizes R&D and costs for the rest of the world. America routinely pays 5x-20x more for drugs than other countries and American grants account for >50% of worldwide medical research funding (caveat: the last time I checked). Yup, even Europe is a fraction of what America pays.
I would encourage you to actually do the math and decide for yourself rather than taking (or anyone else's) word for it.
A much more interesting discussion could be had around who pays for it (and how, and how the prices come to be as high etc.) – because somebody ultimately does.
But I hope you agree that in all of these models, the doctor does in the end get paid, i.e. accepts payment? I never said that the patient should be the one paying them directly. But if nobody does, there will be no doctor.
One of the arguments against this is inflation from creating money out of thin air to fund it. Its a lie. The service is required and you don't get inflation from paying folks a wage to do a job. You do get it by propping up profits of private companies which essentually through the fattening of their bank accounts devalues money. Remember if you have a large number of folks competing for a good or service and they are all on similar playing fields (e.g wages near market avg), competition is high, the value of each dollar earned remains high.
If you have a handful of companies with buying power that far outweighs that of others allowing them to capture more than their share of a service or good because they can literally just throw more money at it than the majority of us can. This drives Inflation. It devalues money creating a new norm of your dollars being worth less.
Tldr: The benefit from entirely gov funded healthcare far outweighs that of a privatized system.
Of course I agree this market should be regulated - like we regulate it in Europe - but at the end some company is investing into drug research in order to make a profit.
Profit enough to survive. But don't take more than your worth. Tbh profiting off medicine is about as low as profiting off weapons manufacturing. You literally make money out of the misery of others.
Thank f#@k I live in a country that has free healthcare. The concept of privatizing the health of your citizens and letting a select few profit from that is absolutely batshit insane.
Things like insulin are long paid off, and the pricing there has generated controversy. People have been charged $1000 a month for it [1].
What’s fair? They are screaming out to be regulated when they behave so badly, and that’s what’s happened with insulin.
[1] https://www.thelancet.com/journals/landia/article/PIIS2213-8...
If you're not distinguishing between insulin extracted from a horse circa 1922 and a modern synthetic analog, well that's just not being honest.
There's good arguments that the modern synthetic analogs are overpriced, but that's a more subtle argument.
And if the US is able to impose maximum pricing that is so much lower, it would seem likely that price gouging was occurring.
They could take the older insulins for $50 a month, no one is stopping them. It's just that those older products are less convenient.
https://www.visualcapitalist.com/cost-of-insulin-by-country/
https://www.rand.org/pubs/research_reports/RRA788-2.html
https://worldpopulationreview.com/country-rankings/cost-of-i...
Frankly the US pays for the cost of the research while the rest of the world just pays for the cost of production.
If you want to fix the cost of insulin products (and many other drugs) in the US you need to figure out how to make everybody else pay for the true costs.
Edit: also your last source there doesn't even know what it's talking about Novolin is a generic brand name for 3 distinct products that have distinct pricing.
Oh come the fuck on, this has been the talking point since the early 2000's. Surely nobody still believes this horse shit. Phizer by itself raked in 50 billion last year alone.
This sympathy for these massive companies in this thread depressing. Big Agg and Big Tech don’t get this free pass.
I guarantee you 100% of that came from the united states.
2023-12-31 $-3,369 2023-09-30 $-2,382 2023-06-30 $2,327 2023-03-31 $5,543
https://www.macrotrends.net/stocks/charts/PFE/pfizer/net-inc...
Genentech developed biosynthetic human insulin using engineered ecoli.
Eli Lilly produced the first of the modern synthetic insulin analogs.
Literally every major breakthrough except the initial bovine extracts were done in the US.
Isn't this how research and science works?
> Let's not be delusional that Denmark is a bastion of cutting edge biological research
Except in this case, it is? All I read seems to point they did push the envelope a lot of times. Do you have some other reason to say this except "psht, get real, it's Denmark"
Top 10 pharma companies, 5/10 are US (2 UK, 2 Swiss, 1 French).
4 of the top 6 for profit margins (from 43%(!) to 19%) are US (Merck is the only outlier, 9th, at 10%).
4 of the top 5 for Sales and Marketing Spend (both on raw dollars and as a percentage of revenue) are US.
3 of the bottom 5 for R&D spend (as a percentage of revenue) are US.
Well, thanks for the update. Correcting a citation an out-of-date article that is - as you admit - apparently still relevant as cited was definitely worth everyone’s time.
https://en.m.wikipedia.org/wiki/Direct-to-consumer_advertisi...
> One key limitation of this study is that most of our analyses used manufacturer gross prices, not manufacturer net prices after rebates and other discounts are applied.16 Given the generally competitive insulin market, rebates in the United States are substantial (Mulcahy, Schwam, et al., 2021; Dickson et al., 2023). After applying a 76 percent manufacturer gross-to-net reduction, U.S. prices were roughly twice as high as those in other countries (compared with nearly ten times as high without the discount). We caution that these results likely underestimate the magnitude of the price differential because we were unable to estimate similar gross-to-net discounts in other countries. If manufacturer net prices in at least some non-U.S. OECD countries are lower than their manufacturer gross prices, the ratio of U.S. to other-country prices would be higher. In addition, because of data limitations, we applied a single U.S. gross-to-net reduction across all insulins. Actual product-specific gross-to-net discounts likely vary along product characteristics (for example, prescription versus over the counter and timing category). As a result, our estimated ratios of U.S. to other countries’ prices for specific insulin categories likely reflect measurement error.
As far as I can tell they also aren't attempting an apples to apples comparison, they're lumping all "long lasting" insulin drugs together. There is no such drug as "insulin", or even "long-lasting insulin". There are dozens of insulin analogs being sold at an incredible range of prices, easily over 10x from the most expensive to the cheapest.
https://www.goodrx.com/healthcare-access/research/how-much-d...
My default take on this kind of analysis is that people in the US are wealthier and are therefore paying for the newer, more effective, more expensive insulin drugs than people in other countries. I'm happy to be proven wrong on this but I haven't ever seen that analysis, they always conspicuously avoid direct comparisons of the same drugs.
The price for healthcare is beyond understanding for mortals. The price for drugs, again you and your neighbour could be paying something completely different for the same medication. The actual cost to your wallet for university? Who know, everyone seems to get different levels of subsidy and scholarship. Visa Cash App - you can make the same purchase on two different days and pay different prices, unique only to you.
I find it incredibly exhausting to visit the US and navigate all these pricing systems, I dont know how you have let this become a psychological status quo.
Here you go kid: https://en.wikipedia.org/wiki/Free-rider_problem
Read that, and then you can explain to me the answer to your question.
That’s not because of an action by the FDA, but just that the manufacturers stopped selling it between 1998 and 2006:
https://www.fda.gov/drugs/frequently-asked-questions-popular...
So your only option is to buy the modern day synthetic analogs - or illegally import the old stuff, which the FDA notes here it has the right to block, but may allow under exceptional circumstances.
My understanding is that the controversy is over a newer type of fast acting insulin that's not yet generic. In general insulin is really cheap, but the really nice new stuff makes life a lot easier for diabetics so everyone wants it.
FTC is finally taking some charge, after all the other agencies (patent office, FDA) have failed to do any enforcement.
Really good recent write up by the usual king of company & capitalism watching, https://www.thebignewsletter.com/p/monopoly-round-up-how-ftc...
And for good reason.
Humalog and NovoLog both have expired patents. There are newer, better insulins. But these drugs were state of the art just 25 years ago.
The newer products are cheaper elsewhere in the world. The US is getting ripped off by big pharma.
However, the blame doesn't lie with pharmaceutical companies. They're not selling their products cheaper elsewhere because they hate the US and love other countries
They're doing it because the US has created a system that benefits corporations more than its citizens. If blame needs to be distributed it lies with the people in power who built these systems and those who gave them that power
Healthcare in Europe is cheaper because the population fought for it, sometimes literally
1. Expensive drugs are expensive to compete again. Any new entrant will have an uphill climb. They will need a new way to solve the problem, so it doesn’t infringe on the incumbents patents.
2. Drug manufacturing is still a niche business. In many other advanced industries, the tooling has become commoditized leading to a lower bar for entry and increase in competition. Repairing phone displays and soldering memory modules is now possible at home. Pharma is still waiting for that 3D printer/indie moment.
I don’t know if it’s even possible - we’re talking about chemicals and amino acids here. Every drug will need a different set of ingredients (not that different from cooking food).
But we are nowhere close to that point. Ozempic is going off patent in 2031. It is a new drug, and it happens to be a miracle drug. Why should the company that brought the drug to market not monetize on it?
Approval of biosimilars, state laws capping price, and manufacturer out of pocket max are driving down the price over the last 4 years.
https://www.goodrx.com/healthcare-access/research/how-much-d...
"Big Pharma spends billions more on executives and stockholders than on R&D" https://news.ycombinator.com/item?id=39405547
I can't believe that I'm sharing YouTube shorts on HN, but this is the best way to share this info at the moment:
Huh.
> Gilead Sciences gross profit for the twelve months ending December 31, 2023 was $20.618B
Not insane profits, indeed.
GILD is down 10%+ YoY. SP500 is up 28% YoY. Or Cigna (health insurance, also 100B market cap) 43% up
Stories like this seem to pretty clearly represent the hazards of private funding for drug research. Publicly funded research and possibly publicly funded drug production could eliminate this issue.
But yeah, people might not like the implementation or idea of intellectual property, but that’s what’s happening here. Pretending it’s something else makes it hard to argue about it.
At the same time, its quite clear that the cost of drugs, particularly in the US is out of control.
In that sense, focusing on the fact that a company that received the technical data package and plant for manufacturing Ozempic for free could then indefinitely sell Ozempic for $5 a month is a red herring, and not likely to lead to any fruitful change. The price differential between US pricing and say... UK pricing ($350 a month for injectable Ozempic vs ~$80 a month) is enough to hammer in on.
On a side note, what I found interesting is that while the article says a injectable Ozempic can cost ~1k a year, the actual study marks it at more like $350 a month.
https://www.ndtv.com/world-news/at-850-000-drug-to-treat-bli...
can be made for .1c
heck, a top of the line AMD server chip costing $10,000 only contains a few milligrams of plastic copper gold and sand.
I mean, let's be realistic here.
How is that realistic?
TBH I have way less a problem with pharma industry being allowed to make profits than health insurance companies. In fact the US is about the only country in the world that allows profits from health insurance.
every other country only allows them to exist as not-for-profits.
whereas expensive medicines just make health insurance less profitable.
This is the basic principle behind why the US spends the most in the world on healthcare to achieve among the worst outcomes (e.g. same life expectancy as most undeveloped 3rd world countries)
The blindness thing has a worldwide demand cap of about 40 doses per year - it's a single dose for life in each eye).
Are you equally surprised when a one-off bespoke PCB costs more than a stock RaspPi?
So why target ozempic for too high a profit margin?
Caveated with its the health insurance industry is paying that profit margin - not the people who _should_ be taking it.
Novo Nordisk is controlled by the Novo Nordisk Foundation (> 77.1% of votes, 28.1% of capital) with aim to make a positive impact on health, science, and society by generating long-term returns on the assets of the Novo Nordisk Foundation.
One of the reasons why Novo Nordisk has been so successful is because their owner takes a long term view in R&D unlike purely profit-seeking owner.
https://www.acquired.fm/episodes/novo-nordisk-ozempic
If you don't want to listen, there is the transcript right there on the page.
In there, they mentioned "It's pretty interesting. Pharma as a whole of the medical pie only occupies about 13% of revenue."
”The administrative costs of health insurance are 8%."
"I will say, who is taking any risk in this whole ecosystem? It's only pharma. Who's taking risk to innovate and make anything better? Every other bet that a hospital makes or that an insurance company is just probably going to pay off."
Say what you will, but pharma is pushing healthcare forward so I am not against them making money. Of course, I also don't want people to have lack of healthcare access because merely money, so there is a line to tow here.
The way insurance and drug pricing works in the US is bonkers and I would not solely blame pharma for that.
Novo Nordisk is applying a pricing strategy that reflects demand and what people are willing to pay.
https://en.wikipedia.org/wiki/Value-based_pricing
There are many, many MANY people in this world will to pay for this on the basis of value. Heck if I had a lazy $5,000 I'd buy 5 months worth of the stuff and I'd be extremely happy with my purchase and I would not care what it cost to make.
Losing 20 kilos is easily worth $5K to me.
The only problem is I can't get it at any price - Wegovy is simply not available here in Australia and for all I know it might take 10 years until they can make enough to supply the market.
If someone could get it for me I would pay them except I'd never trust the black market - you're unlikely to be getting the real thing.
Since pharmaceutical companies are, for the most part, publicly traded they're beholden to stock holders to create a profit. If they stop doing that they're in trouble
If the ability to generate profit from developing new drugs are limited, they'll simply stop doing it
Personally I think this kind of profit incentive for healthcare is perverse and ultimately doesn't serve public interest, but until the systemic issues behind these prices are addressed, I find it difficult to see a solution that'll ultimately benefit the end-user
A single payer system would at least change the negotiating power that big pharma has - even in a small market, drug companies hate dealing with a single buying. Here in New Zealand the point even made it into the TPP agreement negotiations. The US wanting our (deeply imperfect) healthcare system to be a bit more like the US one is rather grim.
There's flaws in this approach as well, but in the end it's definitely an improvement to the issues US patients are facing in regards to costs
In reality those shareholders will pretty much always demand that the company maximise their ROI, so in reality I don't think it matters whether they are required to or not
If they don't they'll be eaten by a company that does and the outcome will be the same
If your point is the price then the US could go after every single US medicine company.
So what did you mean by that?
EU created anti trust laws that makes fining Apple and Google possible.
EU laws prioritize people over corporations.
So EU corps selling in the US can bleed their customers dry, just like the local US corps.
And US corps operating in the EU are restricted in the people's interest, just like the local EU corps.
This is the just application of the respective laws as they stand.
This is the outcome the respective populations voted for.
Although the rest of the world does wonder what the US voters were thinking ...
The stuff basically sells itself at this point; marketing probably doesn’t even register in their budget for it.
We could have all kinds of interesting discussions around the parallels between research funding and tech VCs, sprawling regulations and delayed approval procedures etc., but even in a libertarian utopia without an FDA I think you'll find that all researches like getting paid at the end of the month consistently, and not just the few that do eventually hit the jackpot.
"Ozempic face" has become a meme as people try to guess who is using it.
Several of my neighbors are admittedly using it. And they've lost 30, 40+ pounds in a matter of months. Months.
This is a diabetes drug. There has to be a biochemical catch here.
What if there isn't a catch? Sometimes technology really does just improve the human condition with no serious downsides. Consider refrigeration or sanitary surgical techniques.
https://ourworldindata.org/obesity
https://www.scientificamerican.com/article/could-new-weight-...
I could entirely see this being a net positive for a lot of people, but I want to know what those side effects are.
Long term studies are also not super complete - even something known to cause cancer like smoking or asbestos takes decades to show up.
this drug has side effects on some people but it’s may make obesity a thing of the past. especially if generics could be made so cheaply
Fortunately they don’t regulate access to either for most people in the world.
If you cannot see the dysgenic effects of vaccines, antibiotics, etc I doubt I can convince you in a a single comment. Just take my word for it that the percent of the population that will have permanent defects that require lifelong treatments is continuing to rise. Sperm loads and quality are continuing to drop.
I am not implying that these trade-offs aren't worth making -- just that our collective leadership should be making them with eyes wide open and planning for the inevitable sacrifice each piece of 'progress' requires.
Edit: Just as a simple thought experiment: If these obesity drugs are really the miracles they seem to be, I can see a future in couple generations where any disruption in supply will lead every single person to balloon to the size of the fattest person you have ever seen in your life. What ever gene(s) are regulating satiation will be rendered moot and thus have zero selection pressure. The outsourcing of this function is just that -- the human organism will no longer have any method of regulating hunger, satiation, etc.
Other than that, what’s the problem with a weight loss drug? That it’s “unnatural” or “cheating nature”? The weight gain and the corresponding lifestyle and nutrition that often cause it aren’t exactly nature-given either.
Glycemic control wouldn't be any different between the two at the same dosage but yes, people should really be seeking out Wegovy or Zepbound (tirzepatide) since those actually have a chance of being approved by their insurance for weight loss based on their FDA indication vs Ozempic or Mounjaro.
I’m on Ozempic and not Wegovy. Here’s why:
- Wegovy is impossible to get. I had it prescribed a year ago and it still hasn’t been filled. Multiple pharmacies too.
- In the meantime, my new insurance doesn’t cover it or Ozempic. So I’m out of pocket.
- Ozempic 2mg pens are readily available and unlike Wegovy, you dial the dose, so that 2mg pen lasts me 2 months. It’s not officially indicated and they tell you not to, but just google an Ozempic click chart to see. My doctor was the one who suggested this!
- Wegovy pens don’t have variable dosage. Only Ozempic does.
- Theres no price difference in the pen sizes for Ozempic or Wegovy near me. No matter what dose pen you get, and no matter if it’s Ozempic or Wegovy, it’s $1000 for a 4 dose equivalent of the prescribed amount.
So for me it’s a no brainer if I’m paying retail - give me the highest dose Ozempic pen and I’ll dial the smaller dose that I take. It’ll last me twice as long since I take 1mg weekly. And I can actually get it.
The fact that 0.5, 1, and 2mg dose pens all cost the same tells you how badly we’re getting worked here.
No... The effects are the same because they are exactly the same drug (semaglutide), the difference is the dosing schedule and max dose (wegovy is 2.4mg and ozempic is 2mg).
It was developed as a drug that increases insulin response, but it also appears to have a substantial impact on CNS processes controlling food cravings and other types of desire.
Given that, it’s possible we’ve stumbled upon the mechanism responsible for genetic differences in how we put on weight, whether that’s appetite, metabolic differences or both.
Yikes. I wonder if there could be long term cardiac or pulmonary health issues as a result of this.
I'm also interested if this creates long-term insulin or pancreatic dysfunction.
Someone correct me if I’m wrong
Give it away. The public health benefits will pay for themselves.
Has a half-century of telling people to "simply eat better" worked?
But the reason they have patents that last like 20 years is to allow them to recover the costs of R&D.
As a Dane that's pretty terrifying to me (see Nokia and Nortel)
Novo Nordisk $35 billion in revenue.
GDP of Denmark:$400 billion.
Their revenue is roughly 9% of GDP.
There's a lot of pensions and savings tied up in Novo stock, so a potential downturn would have a catastrophic impact on the danish citizens
The danish economy is, to a large extend, dependent on the stock price of Novo, not its revenue
Novo Nordisk makes 17% of Danish stock index. Vestas and DSV are both 10%
(Foreign investors' ownership of listed Danish shares is over 50%, so I assume the situation is similar to NN when you remove the foundation owned stocks)
If a country's largest company based on market cap is bigger than the next 50 companies combined, is the most popular stock among the countries retail investors, and is the current sole driver of economic growth in said country, that's a significant risk
Making a comparison between the value generated in a country compared to the total price of a company is a way to illustrate how massive the company actually is - same as when making a comparison to how many years I'd need to work to have earned as much as Jeff Bezos net worth
rms and the FSF believe selling software is totally fine as long as you provide source code to your users.
They don't think there's any moral imperative for software to be free as in priced at $0, but software should respect its users' freedom.
Semaglutide is not GLP1, it's a bit different. But it's not the first GLP1 analog. It's not even the first to be approved : AstraZeneca was the first to get a GLP1 agonist approved, in 2005. In fact, it even is used off label for obesity.
Nordisk's big break was convincing the regulators to get it approved for obesity and not just type 2 diabetes.
I want there to be full employment for experts in drug design and testing.
I don’t want Pharma to be a limited profitability industry that slowly loses money and talent to other industries such as tech or entertainment.
I want kids to dream of becoming the next billionaire by develops drug that cures cancer rather than becoming a billionaire by inventing a more addictive social media app.
Talent goes where the money is. If the money gets removed, the innovation will slowly go away. And like with Boeing, it may take decades for the results to be fully realized.
Covid-19 demonstrated how important Pharma was to society. With the vaccines, Pharma yielded a consumer surplus of literally trillions of dollars (just from being able to re-open the economies).
Yes there was academia that had the basic research, but you needed companies and scientists that had years and years of experience designing, testing, productionizing, and distributing medicines and vaccines.
Bicycles.
I don’t see why they should not be allowed to price this product to meet the insanely high demand.
How much it costs to make is irrelevant to the discussion. This drug wouldn’t have existed without Novo Nordisk, they deserve to profit so they can continue making new drugs.
What is next, should we limit the amount of money JK Rowling can make off her books because it is essentially free to produce?